Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escitalopram - Lundbeck A/S

Drug Profile

Escitalopram - Lundbeck A/S

Alternative Names: Cipralex; Entact; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; Sipralexa

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Allergan; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia

Most Recent Events

  • 31 May 2019 Phase-III clinical trials in Generalised anxiety disorder (In adolescents, In children) in USA (PO) (NCT03924323)
  • 26 Apr 2019 Allergan plans a phase III trial for Generalized anxiety disorder (In children, In adolescents) in May 2019 (PO) (NCT03924323)
  • 08 Feb 2019 Phase-III clinical trials in Major depressive disorder (In children; In adolescents) in Japan (PO) before February 2019 (Mochida Pharmaceuticals pipeline, March 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top